1-6 of 6
Anne Westermann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG)

Barbara Eichhorst, MD, Jasmin Bahlo, Anna Maria Fink, MD, Michael Pfreundschuh, Holger Hebart, MD, Georg Maschmeyer, MD, Kathleen Jentsch-Ulrich, MD PhD, Steffen Dörfel, Anne Westermann, Aline Zey, Kirsten Fischer, Clemens-Martin Wendtner, MD, Thomas Noesslinger, MD, Paolo Ghia, MD PhD, Francesc Bosch, MD PhD, Arnon P. Kater, MD PhD, Karl-Anton Kreuzer, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, Sebastian Boettcher, MD, Michael Hallek, MD
Journal: Blood
Blood (2014) 124 (21): 4699.
https://doi.org/10.1182/blood.V124.21.4699.4699
Published: 2014
Journal Articles

Induction Treatment with Alemtuzumab Combined with Polychemotherapy Containing Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Followed By Alemtuzumab Maintenance in Patients with T-Cell Prolymphocytic Leukaemia (T-PLL): First Analysis of a Prospective Multicenter Phase-II-Trial (T-PLL2) Conducted By the German CLL Study Group (GCLLSG)

Natali Pflug, MD, Georg Hopfinger, MD, Paula Cramer, MD, Alexandra Schrader, PhD, Nicole Weit, PhD, Rita Meister, Miriam Thiel, Tanja Annolleck, Anne Westermann, Till M Seiler, MD, Thorsten Zenz, MD, Jan Duerig, MD, Jasmin Bahlo, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD, Anna-Maria Fink, MD, Barbara Eichhorst, MD, Michael Hallek, MD, Marco Herling, MD
Journal: Blood
Blood (2014) 124 (21): 1999.
https://doi.org/10.1182/blood.V124.21.1999.1999
Published: 2014
Journal Articles

First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.

Michael Hallek, MD, Guenter Fingerle-Rowson, MD, PhD, Anna-Maria Fink, MD, Raymonde Busch, Jiri Mayer, MD, Manfred Hensel, MD, Georg Hopfinger, MD, Georg Hess, MD, Ulrich von Gruenhagen, MD, Manuela A. Bergmann, MD, John Catalano, MD, Pier Luigi Zinzano, MD, Federico Caligaris Cappio, MD, John F Seymour, MD, PhD, Alain Berrebi, MD, Ulrich Jaeger, MD, Bruno Cazin, MD, Marek Trneny, MD, Anne Westermann, Clemens-Martin Wendtner, MD, Barbara F. Eichhorst, MD, Peter Staib, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Myriam Mendila, MD, Michael Kneba, MD, PhD, Hartmut Doehner, MD, Stephan Stilgenbauer, MD, Kirsten Fischer, MD
Journal: Blood
Blood (2009) 114 (22): 535.
https://doi.org/10.1182/blood.V114.22.535.535
Published: 2009
Journal Articles

Health Related Quality of Life (HRQOL) in Patients Receiving Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) or Fludarabine and Cyclophosphamide (FC) for First Line Therapy with Advanced Chronic Lymphocytic Leukemia (CLL).

Barbara F. Eichhorst, MD, Kirsten Fischer, Anna- Maria Fink, MD, Guenter Fingerle-Rowson, MD, PhD, Anne Westermann, Clemens-Martin Wendtner, MD, Raymonde Busch, Michael Hallek, MD
Journal: Blood
Blood (2009) 114 (22): 3438.
https://doi.org/10.1182/blood.V114.22.3438.3438
Published: 2009
Journal Articles

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Clinical Trials & Observations
Barbara F. Eichhorst, Raymonde Busch, Stephan Stilgenbauer, Martina Stauch, Manuela A. Bergmann, Matthias Ritgen, Nicole Kranzhöfer, Robert Rohrberg, Ulrike Söling, Oswald Burkhard, Anne Westermann, Valentin Goede, Carmen D. Schweighofer, Kirsten Fischer, Anna-Maria Fink, Clemens M. Wendtner, Günter Brittinger, Hartmut Döhner, Bertold Emmerich, Michael Hallek, the German CLL Study Group (GCLLSG)
Journal: Blood
Blood (2009) 114 (16): 3382–3391.
https://doi.org/10.1182/blood-2009-02-206185
Published: 2009
Includes: Supplemental data
Journal Articles

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Michael Hallek, MD, Guenter Fingerle-Rowson, MD, PhD, Anna- Maria Fink, MD, Raymonde Busch, Jiri Mayer, MD, Manfred Hensel, MD, Georg Hopfinger, MD, Georg Hess, MD, Ulrich von Gruenhagen, MD, Manuela A. Bergmann, MD, John Catalano, MD, Pier Luigi Zinzani, MD, Federico Caligaris Cappio, MD, John Francis Seymour, MBBS, Alain Berrebi, MD, Ulrich Jaeger, MD, Bruno Cazin, MD, Marek Trneny, MD, PhD, Anne Westermann, Clemens-Martin Wendtner, MD, Barbara F. Eichhorst, MD, Peter Staib, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Stephan Stilgenbauer, MD, Myriam Mendila, MD, Michael Kneba, MD, PhD, Hartmut Döhner, MD, Kirsten Fischer, MD
Journal: Blood
Blood (2008) 112 (11): 325.
https://doi.org/10.1182/blood.V112.11.325.325
Published: 2008